The primary objective of this study is to compare the safety and effectiveness of the Cordis Nitinol Carotid Stent and Delivery Systems (5.5 F and 7 F) with the ANGIOGUARD XP distal protective device to CEA in the treatment of carotid artery disease in patients at increased risk for surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,300
composite of major adverse clinical events including death, any stroke, and/or myocardial infarction at 30-days post-procedure
Time frame: 30-days post-procedure
The same 30-day composite of major adverse clinical events plus death and/or ipsilateral stroke between 31-days and 12-months post-procedure.
Time frame: Between day 31 and 12-months post-procedure.
successful stent deployment at the target lesion in a variety of carotid morphologies
successful filter deployment and retrieval
<30% residual stenosis determined by angiography immediately post-stent placement and post-dilatation
endovascular access site complications, such as the need for surgical repair or blood transfusion
surgical site complications, such as wound infection or hematoma, that prolong hospital stay, require incision and drainage, or need blood transfusion
patency (< 50% restenosis) of the Cordis Nitinol Stent as determined by carotid ultrasound imaging within 48 hours, at six months, and one, two and three years post-procedure
independent neurologic assessments at 24 + 12 hours, thirty days, six months, and one, two and three years post-procedure (in addition to stroke scales, the development of any cranial nerve deficits will be recorded) - persistent neurologic deficits
thirty (30)-day and six (6)-month evaluation for disabling stroke
Time frame: Day 30 and 6 months
six (6)-month, one (1)-year, two (2)-year and three (3)-year composite of major adverse clinical events including death and ipsilateral stroke
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 6 month and 1, 2, 3yr
safety assessment of the ANGIOGUARD XP Emboli Capture Guidewire Device
presence of trapped material as determined by the interventionalist's visual inspection of the ANGIOGUARD XP filter basket following recapture at the completion of the procedure
laboratory analysis of trapped material contained in the ANGIOGUARD XP filter basket